Bilirubinuria in Heart Failure: Diagnostic and Therapeutic Guidance

1. Pathophysiological Significance

Bilirubin detected in the urine of a patient with heart failure and proteinuria indicates hepatic congestion or hypoxic liver injury rather than primary renal disease, and should trigger immediate assessment of volume status, cardiac output, and liver function tests. 1
Mild unconjugated hyperbilirubinemia is common in Fontan‑associated liver disease and other congestive hepatopathies, arising from passive venous congestion, impaired hepatic clearance, or less frequently ischemic biliary injury. 1
Deeper jaundice may develop at the end of an episode of hypoxic hepatitis in advanced heart failure, whereas mild jaundice is more typical. 1
Acute cardiac events (e.g., surgery, cardiovascular collapse) can cause dramatic rises in aminotransferases, reflecting hypoxic hepatocellular necrosis. 1

Urine microscopy is essential to differentiate true hematuria from hemoglobinuria or myoglobinuria and provides an excellent negative predictive value for tubular injury. 2

A comprehensive serum liver panel—including total and direct bilirubin, AST/ALT, alkaline phosphatase, γ‑glutamyltransferase (GGT), albumin, and prothrombin time/INR—should be obtained to characterize the pattern of hepatic injury. 1, 3
Mild elevation of GGT is the earliest and most frequent laboratory abnormality in congestive hepatopathy, observed in >85 % of adult Fontan patients. 1
In non‑cirrhotic congestive hepatopathy, prolonged PT/INR reflects passive congestion rather than true synthetic dysfunction. 1

Acute coronary syndrome must be ruled out with cardiac troponin measurement because ischemic events can precipitate both cardiac decompensation and hypoxic hepatitis. 3
In the presence of fever, new murmur, or embolic phenomena, infective endocarditis should be considered as a potential cause of both cardiac decompensation and glomerulonephritis with hematuria. 2
Review of medications for hepatotoxic agents and assessment for hemolysis (e.g., reticulocyte count, haptoglobin, LDH) are required when unconjugated hyperbilirubinemia predominates. 1

Clinical evaluation of volume status (jugular venous distension, peripheral edema, weight trends) should be complemented by invasive hemodynamic monitoring when cardiogenic shock or refractory congestion is suspected. 4
Elevated right atrial pressure independently predicts worsening renal function across the ejection‑fraction spectrum; kidney perfusion pressure (mean arterial pressure − central venous pressure) should be maintained > 60 mmHg. 4

Initiate intravenous loop diuretics at a dose at least equivalent to the patient’s total daily oral dose (or 20–40 mg IV furosemide for diuretic‑naïve patients), with continuous monitoring of urine output, renal function, and electrolytes. 5
For diuretic‑resistant congestion (≥ 240 mg IV furosemide daily without adequate response), add a thiazide‑type diuretic (metolazone or hydrochlorothiazide) for dual‑nephron blockade or switch to a continuous furosemide infusion. 6, 5

Disease‑modifying therapies (beta‑blockers, ACE inhibitors/ARBs, mineralocorticoid receptor antagonists) should be continued throughout acute decompensation unless hemodynamic instability mandates temporary withdrawal. 5
The presence of bilirubinuria or proteinuria alone does not justify discontinuation of heart‑failure medications; the underlying etiology must first be identified. 2
In patients with stable renal function (serum creatinine < 200 µmol/L), standard dosing of ACE inhibitors, ARBs, or spironolactone may be maintained, with more frequent monitoring of potassium and creatinine. 6

Discontinue nephrotoxic and hepatotoxic agents (e.g., NSAIDs, COX‑2 inhibitors) that can precipitate acute kidney injury or worsen hepatic congestion. 6, 5
Adjust supratherapeutic anticoagulation doses, as combined anticoagulation and renal dysfunction markedly increase bleeding risk. 2
Treat precipitating factors such as acute coronary syndrome, uncontrolled hypertension, arrhythmias, infections, and anemia. 5

Serial measurements of serum bilirubin, aminotransferases, and albumin should be performed to track resolution of hepatic congestion and guide adequacy of decongestive therapy. 1
Daily assessment of body weight, urine output, and clinical perfusion (warm vs. cold extremities, capillary refill) ensures appropriate titration of diuretics and inotropes. 4, 5
Renal function and electrolytes should be re‑checked within 1–3 days in advanced heart failure or within 7 days after any significant diuretic regimen change. 7

Attributing bilirubinuria solely to “cardiorenal syndrome” without further investigation can miss treatable causes such as hypoxic hepatitis, acute coronary syndrome, or medication‑induced liver injury. 2
Discontinuing essential heart‑failure medications based only on the presence of bilirubinuria or proteinuria can worsen cardiac outcomes; therapy should be maintained unless hemodynamic instability is confirmed. 2
Using MELD or Child‑Pugh scores to stage liver disease severity in heart failure is inaccurate because these scores incorporate INR, creatinine, and albumin, which may reflect cardiac dysfunction and passive congestion rather than true hepatic synthetic failure. 1